ONYX-015: Phase I/II

ONXX and partner Pfizer Inc. (PFE, New York, N.Y.) reported preliminary results in 4 patients of an ongoing U.S. Phase I/II study showing that ONYX-015 injected intratumorally at up to 1010 pfu/dose ...